Featured ArticlesGlobal Health

Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?

By March 30, 2020April 29th, 2020No Comments

Dermatology News

Featured Article

Dermatologist looking at skin

"Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?"

While the world lives under the shadow of the novel coronavirus (COVID-19) pandemic, dermatologists wonder if the current situation calls for a temporary change in the management of skin conditions.

Immunosuppressive drugs are used ubiquitously in the modern treatment of inflammatory and autoimmune skin diseases like psoriasis, bullous diseases, connective tissue diseases, and many others. Treatment of these conditions is based on the suppression of the patient’s immune system using steroids, steroid-sparing drugs, and biological agents.1
“The use of immunosuppressive to treat these conditions can amplify this effect, and it might leave the patient vulnerable to more serious complications should an infection with the novel coronavirus be established. Hence, it may be wise to restrict temporarily the use of immunosuppressive agents including systemic steroids, steroid-sparing agents, and biologics in dermatology daily practice until more evidence is avilable about their safety in the current pandemic.6 As a relates point, the International Psoriasis Council declared an urgent statement on March 11, 2020 that the physician should be alert to the potentially harmful effects of COVID-19 infection on patients with psoriasis and to immediately discontinue or postpone immunosuppressant medications for psoriasis patients diagnosed with COVID-19 disease.”

As the declaration of the novel coronavirus as a pandemic by the WHO is a trending topic nowadays, dermatologists around the world view with concern the impact of this pandemic on their daily practice.

Read Full Article Now

You May Also Like

Journal of Drugs in Dermatology JDD Article About Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical InterventionsAtopic DermatitisFeatured ArticlesLatest NewsThe Latest
June 27, 2025

Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions

Beyond Minoxidil: Is It Time to Rethink Female Hair Loss Treatment? More than half of postmenopausal women, and a significant percentage of younger, healthy women, struggle with visible hair loss,…
Journal of Drugs in Dermatology JDD Article About Socioeconomic Disparities in Gentle Skin Care Access for Atopic Dermatitis: Affordability and Pharmacy Deserts. Image is of deeper skin tone patient’s back covered with erythema, red atopic dermatitis.Atopic DermatitisFeatured ArticlesLatest NewsThe Latest
June 26, 2025

Socioeconomic Disparities in Gentle Skin Care Access for Atopic Dermatitis: Affordability and Pharmacy Deserts

Access Inequity in Atopic Dermatitis Care: Are Your Patients Getting Left Behind? Gentle skin care is a foundation of atopic dermatitis (AD) treatment, but what happens when patients can’t afford,…
Journal of Drugs in Dermatology JDD Article About world vitiligo day. The image is from The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas of a patient with skin of color who has vitiligo on the scalp, face, and forehead. The patient has darker skin tone.DyspigmentationFeatured ArticlesLatest NewsMelasmaSkin of ColorThe LatestVitiligo
June 25, 2025

World Vitiligo Day

June 25 marks World Vitiligo Day, a global recognition of a condition that affects approximately 0.5-2% of the population worldwide. Though non-life-threatening, vitiligo carries a profound psychosocial burden, disproportionately affecting…

Leave a Reply